Aculys Pharma is a biopharmaceutical company focused on the development and commercialization of innovations in the fields of neurology and psychiatry.
The proceeds of the Series A financing support the clinical development and commercialization of Pitolisant in Japan for the treatment of sleep disorders.
Location: Japan, Kanagawa Prefecture, Fujisawa
Employees: 1-10
Total raised: $84M
Founded date: 2021
Investors 4
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
| 02.12.2021 | Catalys Pa... | catalyspac... |
| - | JIC Ventur... | j-vgi.co.j... |
| 04.04.2022 | Spiral Cap... | spiral-cap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.03.2022 | Series B | $24M | - |
| 29.10.2021 | Series A | $60M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 01.04.2024 | Aculys Pharma Announces Appointment of Hidemasa Tanigaki as ... | ～Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS in Japan and Asia～... | en.prnasia... |
| 18.10.2023 | Aculys Pharma delivers positive Phase 3 clinical study inter... | These results are from Japan's first domestic Phase 3 clinical trial of an intranasally administered... | en.prnasia... |
| 25.01.2023 | Aculys Pharma Initiates Phase 3 Trial of Pitolisant Treating... | Aculys Pharma, a clinical stage biopharmaceutical company focused on commercializing innovative trea... | aithority.... |
| 24.01.2023 | Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treati... | This trial is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study (Pa... | catalyspac... |
| 10.11.2022 | Aculys Pharma initiates a phase 3 clinical study of a diazep... | This phase 3 study, conducted in Japan, is a multi-center, open-label study in children with status ... | catalyspac... |
| 08.11.2022 | Aculys Pharma initiates a phase 3 clinical study of the hist... | This phase 3 study consists of a multi-institutional double-blind, randomized, placebo-controlled, p... | catalyspac... |
| 28.03.2022 | 神経・精神疾患領域に特化したバイオベンチャー企業であるアキュリスファーマ株式会社へ出資しました... | 当社は、Spiral Capital Japan Fund 2号投資事業有限責任組合を通じて、神経・精神疾患領域における革新的な医薬品を開発するアキュリスファーマ株式会社へ出資を行いました。 アキュリ... | spiral-cap... |
| 28.03.2022 | Aculys Pharma Closes US$24 Million Series B Financing | Kazunari Tsunaba, Co-founder, Chief Executive Officer and Representative Director of Aculys said, “A... | catalyspac... |
| 04.02.2022 | Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisa... | Aculys Pharma has an exclusive licensing agreement for the clinical development and commercializatio... | catalyspac... |
| 26.01.2022 | Aculys Pharma signed an exclusive licensing agreement with N... | Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representativ... | catalyspac... |
Show more